Anti-IGF2 ADCC Enhanced Antibody (DX-2647) is an ADCC enhanced antibody produced by our Afuco™ platform. This is a human monoclonal antibody against insulin-like growth factor-II that blocks the growth of human hepatocellular carcinoma cell lines in vitro and in vivo. DX-2647 inhibited IGF-II and, to a lesser extent, IGF-I-induced receptor tyrosine phosphorylation, cellular proliferation, and both anchorage-dependent and anchorage-independent colony formation in various cell lines. In addition, DX-2647 slowed tumor progression in the Hep3B xenograft model, causing decreased tumoral CD31 staining as well as reduced IGF-IIE and IGF-IR phosphorylation levels. Therefore, DX-2647 offers an alternative approach to targeting IGF-IR, blocking IGF-II signaling through both IGF-IR and IR-A.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-740 | Anti-IGF2 Recombinant Antibody (Dusigitumab) | Neut, ELISA, IF, IP, FuncS, FC, ICC | IgG2 |
TAB-387CL | Anti-Human IGF2 Recombinant Antibody (DX-2647) | BL, Inhib | Antibody |
There are currently no Customer reviews or questions for AFC-372CL. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.